Literature DB >> 29272161

Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?

Paul D Brown1, Manmeet S Ahluwalia1, Osaama H Khan1, Anthony L Asher1, Jeffrey S Wefel1, Vinai Gondi1.   

Abstract

An estimated 20% of patients with cancer will develop brain metastases. Approximately 200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) each year to treat brain metastases. Historically, the prognosis of patients with brain metastases has been poor; however, with new therapies, this is changing. Because patients are living longer following the diagnosis and treatment of brain metastases, there has been rising concern about treatment-related toxicities associated with WBRT, including neurocognitive toxicity. In addition, recent clinical trials have raised questions about the use of WBRT. To better understand this rapidly changing landscape, this review outlines the treatment roles and toxicities of WBRT and alternative therapies for the management of brain metastases.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29272161      PMCID： PMC6075843          DOI： 10.1200/JCO.2017.75.9589

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


  55 in total

1.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

3.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

Authors:  Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascierto; Paul B Chapman; Igor Puzanov; Axel Hauschild; Caroline Robert; Alain Algazi; Laurent Mortier; Hussein Tawbi; Tabea Wilhelm; Lisa Zimmer; Julie Switzky; Suzanne Swann; Anne-Marie Martin; Mary Guckert; Vicki Goodman; Michael Streit; John M Kirkwood; Dirk Schadendorf
Journal:  Lancet Oncol       Date:  2012-10-08       Impact factor: 41.316

4.  Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial.

Authors:  Stephen R Rapp; L Doug Case; Ann Peiffer; Michelle M Naughton; Michael D Chan; Volker W Stieber; Dennis F Moore; Steven C Falchuk; James V Piephoff; William J Edenfield; Jeffrey K Giguere; Monica E Loghin; Edward G Shaw
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

5.  Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.

Authors:  Paul D Brown; Stephanie Pugh; Nadia N Laack; Jeffrey S Wefel; Deepak Khuntia; Christina Meyers; Ali Choucair; Sherry Fox; John H Suh; David Roberge; Vivek Kavadi; Soren M Bentzen; Minesh P Mehta; Deborah Watkins-Bruner
Journal:  Neuro Oncol       Date:  2013-08-16       Impact factor: 12.300

6.  Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.

Authors:  Reinhard Dummer; Simone M Goldinger; Christian P Turtschi; Nina B Eggmann; Olivier Michielin; Lada Mitchell; Luisa Veronese; Paul René Hilfiker; Lea Felderer; Jeannine D Rinderknecht
Journal:  Eur J Cancer       Date:  2013-11-29       Impact factor: 9.162

7.  Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Authors:  Nancy U Lin; Véronique Diéras; Devchand Paul; Dominique Lossignol; Christos Christodoulou; Hans-Joachim Stemmler; Henri Roché; Minetta C Liu; Richard Greil; Eva Ciruelos; Sibylle Loibl; Stefania Gori; Andrew Wardley; Denise Yardley; Adam Brufsky; Joanne L Blum; Stephen D Rubin; Bernie Dharan; Klaudia Steplewski; Denise Zembryki; Cristina Oliva; Debasish Roychowdhury; Paolo Paoletti; Eric P Winer
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

8.  Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.

Authors:  Masaaki Yamamoto; Toru Serizawa; Takashi Shuto; Atsuya Akabane; Yoshinori Higuchi; Jun Kawagishi; Kazuhiro Yamanaka; Yasunori Sato; Hidefumi Jokura; Shoji Yomo; Osamu Nagano; Hiroyuki Kenai; Akihito Moriki; Satoshi Suzuki; Yoshihisa Kida; Yoshiyasu Iwai; Motohiro Hayashi; Hiroaki Onishi; Masazumi Gondo; Mitsuya Sato; Tomohide Akimitsu; Kenji Kubo; Yasuhiro Kikuchi; Toru Shibasaki; Tomoaki Goto; Masami Takanashi; Yoshimasa Mori; Kintomo Takakura; Naokatsu Saeki; Etsuo Kunieda; Hidefumi Aoyama; Suketaka Momoshima; Kazuhiro Tsuchiya
Journal:  Lancet Oncol       Date:  2014-03-10       Impact factor: 41.316

9.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

10.  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.

Authors:  Paula Mulvenna; Matthew Nankivell; Rachael Barton; Corinne Faivre-Finn; Paula Wilson; Elaine McColl; Barbara Moore; Iona Brisbane; David Ardron; Tanya Holt; Sally Morgan; Caroline Lee; Kathryn Waite; Neil Bayman; Cheryl Pugh; Benjamin Sydes; Richard Stephens; Mahesh K Parmar; Ruth E Langley
Journal:  Lancet       Date:  2016-09-04       Impact factor: 79.321
View more
  43 in total

1.  Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases.

Authors:  Valerio Nardone; Sara Nanni; Pierpaolo Pastina; Claudia Vinciguerra; Alfonso Cerase; Pierpaolo Correale; Cesare Guida; Antonio Giordano; Paolo Tini; Alfonso Reginelli; Salvatore Cappabianca; Luigi Pirtoli
Journal:  Strahlenther Onkol       Date:  2019-05-23       Impact factor: 3.621

2.  Long-term disease outcome and volume-based decision strategy in a large cohort of multiple brain metastases treated with a mono-isocentric linac-based Stereotactic Radiosurgery technique.

Authors:  F Alongi; L Nicosia; V Figlia; N Giaj-Levra; F Cuccia; R Mazzola; F Ricchetti; M Rigo; C Vitale; A De Simone; S Naccarato; G Sicignano; D Gurrera; S Corradini; R Ruggeri
Journal:  Clin Transl Oncol       Date:  2021-02-11       Impact factor: 3.405

3.  Type and timing of systemic therapy use predict overall survival for patients with brain metastases treated with radiation therapy.

Authors:  Kevin Yijun Fan; Nafisha Lalani; Nathalie LeVasseur; Andra Krauze; Fred Hsu; Lovedeep Gondara; Kaylie Willemsma; Alan McVey Nichol
Journal:  J Neurooncol       Date:  2020-11-18       Impact factor: 4.130

Review 4.  Current approaches to the management of brain metastases.

Authors:  John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang
Journal:  Nat Rev Clin Oncol       Date:  2020-02-20       Impact factor: 66.675

Review 5.  Clinical outcomes of brain metastases from hepatocellular carcinoma: a multicenter retrospective study and a literature review.

Authors:  Takeshi Okuda; Nakamasa Hayashi; Masamichi Takahashi; Takeo Uzuka; Yoshiko Okita; Ryohei Otani; Toshiyuki Fujinaka; Mitsugu Fujita; Amami Kato; Yoshitaka Narita; Yoko Nakasu
Journal:  Int J Clin Oncol       Date:  2018-07-02       Impact factor: 3.402

6.  Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.

Authors:  Zhenzhou Yang; Yan Zhang; Rongqing Li; Abulimiti Yisikandaer; Biyong Ren; Jianguo Sun; Jianjun Li; Long Chen; Ren Zhao; Juying Zhang; Xuefeng Xia; Zhongxing Liao; David P Carbone
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

7.  Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study.

Authors:  Montse Alemany; Marta Domènech; Andreas A Argyriou; Noelia Vilariño; Carles Majós; Pablo Naval-Baudin; Anna Lucas; Ramón Palmero; Marta Simó; Ernest Nadal; Jordi Bruna
Journal:  Ann Transl Med       Date:  2021-04

8.  In Vivo Imaging of the Microglial Landscape After Whole Brain Radiation Therapy.

Authors:  Brendan S Whitelaw; Sean Tanny; Carl J Johnston; Ania K Majewska; M Kerry O'Banion; Brian Marples
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-07-24       Impact factor: 7.038

Review 9.  Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib.

Authors:  Lara Ulrich; Alicia F C Okines
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-05-26

10.  Prior nasal delivery of antagomiR-122 prevents radiation-induced brain injury.

Authors:  Haihong Zhou; Furong Sun; Mingqian Ou; Yu Zhang; Meijun Lin; Liqin Song; Yangsheng Yu; Haojie Liao; Weihao Fan; Huaijie Xing; Minhua Li; Kui Zhao; Xiaolian Wu; Yuanhong Sun; Chunmei Liang; Yujie Cai; Lili Cui
Journal:  Mol Ther       Date:  2021-06-24       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.